Background: The biological perturbation associated with psychological and surgical stress is implicated in cancer recurrence. Preclinical evidence suggests that beta-blockers can be protective against cancer progression. We undertook a meta-analysis of epidemiological and perioperative clinical studies to investigate the association between beta-blocker use and cancer recurrence (CR), disease-free survival (DFS), and overall survival (OS). Methods: Databases were searched until September 2017, reported hazard ratios (HRs) pooled, and 95% confidence intervals (CIs) calculated. Comparative studies examining the effect of beta-blockers (selective and non-selective) on cancer outcomes were included. The Newcastle Ottawa Scale was used to assess methodological quality and bias. Results: Of the 27 included studies, nine evaluated the incidental use of non-selective beta-blockers, and ten were perioperative studies. Beta-blocker use had no effect on CR. Within subgroups of cancer, melanoma was associated with improved DFS (HR 0.03, 95% CI 0.01e0.17) and OS (HR 0.04, 95% CI 0.00e0.38), while endometrial cancer had an associated reduction in DFS (HR 1.40, 95% CI 1.10e1.80) and OS (HR 1.50, 95% CI 1.12e2.00). There was also reduced OS seen with head and neck and prostate cancer. Non-selective beta-blocker use was associated with improved DFS and OS in ovarian cancer, improved DFS in melanoma, but reduced OS in lung cancer. Perioperative studies showed similar variable effects across cancer types, albeit from a limited data pool. Conclusion: Beta-blocker use had no evident effect on CR. The beneficial effect of beta-blockers on DFS and OS in the epidemiological or perioperative setting remains variable, tumour-specific, and of low-level evidence at present.
Beta-adrenergic receptor antagonists (beta-blockers) have been used since the 1960s for the treatment of hypertension, ischaemic heart disease, and anxiety disorders. 1 Recent preclinical evidence suggests that beta-blockers may have a protective effect against cancer progression. Betaadrenoceptors (bAR) 2 are present on cancer and immune cells 3 and bAR signalling accelerates cancer spread. 4 In vivo studies have shown that b-blocker treatment may prevent metastasis by inhibiting tumour cell invasion, 2,4e6 tumourassociated inflammation, and vasculature remodelling to limit tumour cell dissemination.
5,7
The perioperative period is a critical stage of a patient's cancer journey. While surgery is essential for the curative treatment of many solid tumours, the biological perturbation associated with the surgical stress response has been increasingly implicated in cancer recurrence. 8e10 Studies in mouse models of cancer show that surgical stress elevates tumour cell retention in metastatic target organs, and these effects may be blocked by beta-blockers. 11 To date, a variable association between beta-blocker use and cancer outcomes is reported in clinical cohort studies. A systematic review and meta-analysis was undertaken to investigate the clinical relationship between beta-blocker use and cancer recurrence (CR), disease-free survival (DFS), and overall survival (OS). The analysis investigated the effect of coincidental beta-blocker (selective and non-selective) use at cancer diagnosis (referenced as epidemiological studies), and specifically in patients undergoing surgery (referenced as perioperative studies) on long-term cancer outcomes. Studies were also analysed for immortal time bias (ITB), a bias created when a period exists during which the outcome of interest for one of the cohorts cannot possibly occur because of the study design. 12 Also known as survivor (ship) bias, 12, 13 ITB has been noted to over-represent patients with high mortality in the no treatment group and patients with low mortality in the treatment group. 14 
Methods

Protocol and registration
This systematic review was conducted in accordance to the Cochrane methodology and the results are reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The review protocol was registered with PROSPERO (Registration Number: CRD42015030102).
Systematic literature search
The following electronic databases were searched for periods up to and including September 2017: Medline (Ovid, 1946epresent), EMBASE (Ovid, 1947epresent), Web of Science (ThomsoneReuters, 1900epresent) , and all components of the Cochrane Library (Wiley, all years). The systematic search excluded animal-only and non-English publications and was limited to studies in adult patients. To maximise sensitivity, each database was searched using two different search strategies and the results merged. The first strategy focused on beta-blocker use and cancer recurrence or survival, and the second strategy targeted the surgical stress response and cancer recurrence or survival. The search strategies contained a combination of controlled vocabulary (e.g. MeSH, EMTREE) and keyword terms and phrases searched in titles, abstracts, and keyword fields as appropriate. Both drug class and generic names of commonly used adrenergic agents (beta-blockers and beta-agonists) and catecholamines (in particular epinephrine, norepinephrine, noradrenaline, and adrenaline), and sympathetic stress response terms were included in the search strategies. An EndNote library was used to manage retrieved records and for de-duplication. The detailed search strings used in the Medline database are listed in Supplementary Digital Content 1.
Study selection and eligibility criteria
Three reviewers (A.Y., J.D., and R.S.) independently screened all retrieved records. Disagreements were resolved through discussion and consensus. When no consensus was reached, an additional investigator acted as an adjudicator (B.R.).
Comparative studies (i.e. cohorts and caseecontrol studies) that examined the effect of any of the beta-blockers (selective and non-selective) on cancer outcomes (e.g. recurrence, relapse, metastasis, disease progression, survival, mortality) were included. Studies evaluating beta-blockers in non-solid organ tumours or evaluating the effect of beta-blockers on the epidemiological risk of developing cancer were excluded. 
Data collection process and data items
Statistical analysis
Analyses were conducted using RevMan 5.2.3 and STATA Version 14 for meta-regression (StataCorp LP, College Station, TX, USA). We transformed reported hazard ratio (HR) estimates into log hazard ratesda recommended single summary statistic for quantifying the treatment effect in studies reporting survival data. The extracted 95% confidence intervals (95% CIs) were transformed to standard errors. The generic inversevariance method with random-effects model was used for pooled estimates. When more than one data set was provided, the post cancer diagnosis beta-blocker data and adjusted ratios after cancer diagnosis were used for the primary analyses. If data were not provided in HR or there were missing or incomplete data, an attempt was made to contact the original study authors. Comparisons within the meta-analysis explored the use of 'any' vs 'no' b-blocker use in all the studies. Sub-analyses investigated 'non-selective' vs 'no' beta-blocker use, the perioperative use of beta-blockers, and cancer type.
Assessment of bias in individual studies
Two investigators (A.Y. and J.D.) independently assessed methodological quality using the NewcastleeOttawa Scale (NOS). The NOS is a validated tool for the assessment of bias in non-randomised studies. 15 The tool uses a scoring system to judge the selection process of the study groups (up to 4 points), the comparability of the groups (up to 2 points), and the ascertainment of exposure and outcome in the studies (up to 3 points). A maximum score of 9 points can be obtained, with studies with scores 7 points generally regarded as having higher quality and a lower risk of bias. 16 Discrepancies were resolved by consensus and when this was not reached a third person (R.S.) acted as an adjudicator.
Risk of bias across studies and additional analyses
A funnel plot and a regression asymmetry test 17 was performed to assess publication bias and small-study effects in the meta-analyses for overall survival. When the estimates differed substantially among the pooled studies (c 2 test, P>0.10), potential predictors of heterogeneity were explored through sub-group analysis, sensitivity analysis by type of estimate (adjusted or unadjusted), or meta-regression to explore the effect of study quality on the results. 18 We also evaluated for the impact of ITB.
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Results
Study selection and characteristics
Sixty-four studies matched the eligibility criteria ( Fig. 1 ) and data for quantitative synthesis were available in 27 studies (Table 1) . 19e45 The majority of studies used b 1 AR selective beta-blockers. All the studies were cohort studies and two studies were prospective. 38, 44 Two studies evaluated the effect of beta-blockers in more than one cancer type. 29, 37 Nine studies evaluated non-selective beta-blocker use at cancer diagnosis 24 Beta-blocker use in any setting (epidemiological or perioperative)
Cancer recurrence
Seven studies (six retrospective 21, 22, 28, 30, 32, 34 and one prospective 38 ) evaluated CR in patients receiving 'any' vs 'no' beta-blocker (Fig. 2) . None of the results were statistically significant. Two studies 30, 38 evaluated CR in patients receiving 'non-selective' beta-blockers but no significant effect was observed on CR.
A subgroup analysis was undertaken to determine if the study design (retrospective vs prospective) contributed to the heterogeneity of the final result for 'any' vs 'no' beta-blocker use and CR. In this subgroup analysis, it was noted that there was statistical difference between the one prospective study 38 and the retrospective studies, 21 : HR 0.08, 95% CI 0.03e0.22; P<0.01). In a subgroup analysis looking at study design, no statistically significant differences were observed between the one prospective study 44 and the retrospective studies (P¼0.34).
24,31,41
Overall survival
Eighteen studies, 19,20,23e27,29,31,32,35,37,39e43,45 all retrospective, investigated the association between 'any' vs 'no' beta-blocker use and OS (Fig. 4) . The pooled HR found no association with b-blocker use and overall survival (HR 1.00, 95% CI 0.90e1.12;
P¼0.99). Exploring cancer types, beta-blocker use was associated with improved OS in patients with melanoma (one study 25 : HR 0.04, 95% CI 0.00e0.38; P<0.01) but decreased OS in endometrial (one study 35 : HR 1.50, 95% CI 1.12e2.00; P<0.01), head and neck (one study 31 : HR 1.64, 95% CI 1.23e2.20; P<0.01), and prostate cancer (two studies 29, 37 : HR 1.31, 95% CI 1.01e1.68; P¼0.04). Seven studies (six retrospective 24, 31, 37, 39, 41, 42 and one prospective 44 ) examined the effect of 'non-selective' beta-blocker use on OS. The pooled HR for all cancer types was not statistically significant. Examining cancer types, disparity was noted in single studies, with improved OS observed with nonselective beta-blocker use in ovarian cancer (one study 41 : HR 0.08, 95% CI 0.03e0.22; P<0.01) and reduced OS reported in lung cancer (one study 42 : HR 1.26, 95% CI 1.06e1.49; P¼0.01).
The only prospective study, by De Giorgi and colleagues, 44 found no association with OS with non-selective betablocker use in patients with melanoma (HR 0.64, 95% CI 0.10e3.96; P¼0.63). In a subgroup analysis assessing study design, no statistically significant difference was found between the one prospective study 44 and the retrospective studies. 24, 31, 37, 39, 41, 42 Beta-blocker use in the perioperative setting
Supplementary 
Risk of bias across studies
The majority (93%) of the studies had a total NOS score 7.
Removing studies 19, 20, 22, 24, 28, 32, 41, 43, 45 with a risk of ITB from the analysis resulted in an associated reduction in CR in patients with breast cancer or an associated improvement in OS in patients with ovarian cancer using any beta-blocker in the perioperative period (Supplementary Table S2) . Two studies 25, 26 were excluded from the ITB analysis as there was not enough information available to determine if there was a risk of ITB. Egger's test showed no evidence for publication bias even when outliers were removed. When studies with extrapolated data from 'risk of metastasis' or 'relapse-free survival' were removed from the analysis of cancer recurrence, no differences were observed in any of the outcomes.
Discussion
We conducted a meta-analysis investigating the effect of beta-blockers on long-term cancer outcomes in both the epidemiological (non-perioperative) and perioperative settings. Based on the mostly retrospective studies identified, the use of beta-blockers in patients with cancer appears to have no consistent association with cancer recurrence or survival in either the epidemiological or perioperative setting. Beta-blocker use may be associated with better outcomes in specific types of cancer (e.g. melanoma and ovarian cancer), while an opposite effect was observed in patients with endometrial, prostate, head and neck, or lung cancer. The lack of causal relationship and specificity 46 between betablocker therapy and long-term cancer outcomes in the epidemiological studies examined (Supplementary Table S3 ) may reflect the paucity of data but may also reflect the underlying heterogeneity in the response of cancer subtypes to beta-blocker modulation.
Differential bAR subtype expression (b 1 , b 2, or b 3 ) 47 is found on cancer cells and immune cells, and activation of these receptors in different cancer types has diverse effects on the tumour microenvironment (tumour proliferation, migration and invasion). 48 Importantly, in vivo studies that explore the effects of bAR signalling suggest a key role for the b 2 AR in modulating tumour outcomes, and typically investigated bblockade using propranolol, a non-selective beta-blocker. 3e5, 7, 11, 49 In contrast, the majority of clinical studies included in this meta-analysis investigated effects from the b 1 AR-selective blocker, metoprolol. Where the use of nonselective beta-blockers were analysed, an improvement in DFS and OS was noted for patients with ovarian cancer, although the results were from a single study by Watkins and colleagues. 41 This study does, however, support the in vitro evidence that ovarian cancer is affected by activation of the b 2 adrenergic pathway, and thus susceptible to blockade by propranolol. 49 The potential benefit of non-selective beta-blockers in the perioperative setting on CR and OS is supported by recent randomised placebo-controlled trials by Zhou and colleagues 50 and Shaashua and colleagues. 51 In these perioperative studies of patients with breast cancer, propranolol treatment preserved the anticancer immunological profiles of peripheral blood mononuclear cells, and reduced epithelial-tomesenchymal transition and activity of prometastatic and proinflammatory transcription factors in excised tumours when compared with placebo. In addition, Shaashua and colleagues 51 suggested a synergistic beneficial effect may be revealed with the concurrent administration of antiinflammatory and beta-blocker interventions. Several prospective clinical trials are currently assessing propranolol use in patients with breast (NCT00502684, NCT01847001, NCT02596867), ovarian (NCT01308944, NCT01504126), melanoma (NCT01988831), and colorectal cancer (NCT00888797) and will shed additional light on oncological outcomes after surgery. In contrast to the POISE study 52 which investigated the effects of perioperative metoprolol, the above clinical trials 53, 54 In our meta-analysis, we considered ITB and excluded potentially affected studies in a subgroup analysis. 19, 20, 22, 24, 28, 32, 41, 43, 45 Correcting for ITB had no substantive effect on our results: the only changes noted were an associated reduction in breast CR, and improved OS in ovarian cancer patients taking any type of beta-blocker perioperatively. Furthermore, after correction for ITB, only a single perioperative study (rather than pooled data) remained for the perioperative analysis, which is a significant limitation. Another major limitation of this meta-analysis is the significant heterogeneity of conditions analysed in the studies, including the large number of cancer types, the variety of betablockers used, the indications for beta-blocker use (e.g. confounding by indication in the epidemiological setting), and the unknown differences in bAR expression on each cancer type and on immune cells. Furthermore, inadequate data on the various cancer treatment regimens (such as chemotherapy, radiotherapy and surgery) and staging of the disease may account for the conflicting results across cancer types, limiting the ability to detect an association between beta-blocker use and long-term cancer outcomes.
In summary, this meta-analysis of clinical studies has found that beta-blocker use has no overall effect on cancer recurrence, disease-free survival and overall survival. Within cancer subgroups, the beneficial effect of beta-blockers remains variable, tumour-specific, and of low-level evidence at present. Given the persuasive in vivo findings and recent prospective clinical evaluation of beta-blockers, 44, 51 further clinical evaluation within specific cancer subtypes using randomised controlled trials will determine if beta-blockers have a therapeutic benefit in cancer recurrence and survival. 
